<p>通过超过 70 年的卓越职业生涯，沃伦·巴菲特展示了成功投资的蓝图。他的纪律性方法，专注于基本面强劲的高质量公司，并以长期视角为基础，在 2025 年初股市波动的背景下，或许比以往任何时候都更为重要。</p>
<p>在巴菲特的领导下，<strong>伯克希尔·哈撒韦</strong>(NYSE: BRK.A)(NYSE: BRK.B) 在过去几十年中击败了 <strong>标准普尔 500 指数</strong>(^GSPC 1.81%) 的回报，甚至在撰写时以令人印象深刻的 9% 的年初至今回报率超越了它。该集团的股票投资组合为零售投资者提供了一个坚实的投资思路起点。</p>
<p>以下是我认为现在值得强烈购买的两只巴菲特股票。最棒的是，你只需不到 300 美元就可以购买每只股票的一股，开始你的投资组合。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTQyMTIvZGVmZW5zaXZlLXN0b2Nrcy13YXJyZW4tYnVmZmV0dC1vd25zLmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTQyMTIvZGVmZW5zaXZlLXN0b2Nrcy13YXJyZW4tYnVmZmV0dC1vd25zLmpwZyZ3PTcwMA"/></p>
<p>图片来源：The Motley Fool。</p>
<h2>1. 克罗格</h2>
<p>由于市场对美国经济强度的焦虑以及特朗普政府新贸易关税即将产生的影响，今年的投资环境变得具有挑战性。然而，<strong>克罗格</strong>(KR 0.52%) 的股票却逆势而上，年初至今回报率达到了 9%。</p>
<p>这家杂货连锁店在多个品牌下运营超过 2700 家门店，包括 King Soopers、Ralphs 和 Smith's。作为消费品领域的领导者，该公司持续盈利并产生强劲的自由现金流，这与巴菲特传统上青睐的投资类型相符。实际上，伯克希尔·哈撒韦拥有该公司 7.6% 的流通股。</p>
<p>更重要的是，克罗格的财务业绩和前景依然稳健，捕捉到不受贸易战影响的食品稳定需求。对于 2025 年，该公司预计销售将持续增长，目标调整后的每股收益（EPS）在 4.60 美元至 4.80 美元之间，较去年中值增长 5.1%。</p>
<p>克罗格作为一只股息增长股票脱颖而出，在过去五年中将季度支付翻倍，当前每股支付为 0.32 美元，收益率为 1.9%。</p>
<p>管理层最近的评论表达了对进一步股息增长的信心，同时还在进行股票回购授权。克罗格简单而高质量的业务为股票提供了更多上涨空间，长期回报股东。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png"/></p>
<p>KR 股息收益率数据来源于 YCharts</p>
<h2>2. 达维塔</h2>
<p><strong>达维塔</strong>(DVA 1.38%) 是另一只可以代表防御性投资的巴菲特股票，能够抵御经济波动。这家医疗巨头是美国最大的医疗服务提供商之一，在 13 个其他国家也在不断扩展，专注于肾脏透析服务。</p>
<p>去年为超过 281,000 名患者提供服务，进行了超过 2900 万次透析治疗，该业务受益于治疗的重复性和救命特性，受到美国终末期肾病（ESRD）项目中独特联邦立法的覆盖，扩大了对患者的医疗保险覆盖。</p>
<p>很容易看出巴菲特为何喜欢这个高盈利的行业领导者。伯克希尔·哈撒韦拥有该公司约 44% 的流通股，这是自 2011 年首次购买以来逐步建立的股份。</p>
<p>截至 2024 年 12 月 31 日的完整年度，总收入为 128 亿美元，同比增长 5.6%。或许更大的故事是盈利能力的跃升，调整后的每股收益达到 9.68 美元，比去年增长 26%，这得益于更高的定价和医疗保险报销率。如今，达维塔作为一个引人注目的投资机会脱颖而出，结合了持续的盈利增长和吸引人的估值。</p>
<p>尽管过去一年股票上涨了 8%，但其股票的交易价格仅为 2025 年每股收益的 13 倍，作为前瞻性市盈率（P/E），远低于该公司 10 年平均的收益倍数，后者接近 17。我认为达维塔的股票被低估，并且在未来几年有良好的回报潜力——这一观点巴菲特可能会赞同。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png"/></p>
<p>DVA 市盈率（前瞻性）数据来源于 YCharts</p>
<h2>为什么这些股票是赢家</h2>
<p>尽管股市在短期内可能不可预测，但巴菲特坚定的耐心和对长期战略的承诺为每位投资者提供了重要的教训。在我看来，克罗格和达维塔是适合多元化投资组合的优秀股票，可以应对任何市场环境。</p>

克罗格

<p>沃伦·巴菲特的投资策略强调高质量公司及其强大的基本面。目前，有两只股票脱颖而出：克罗格和达维塔。克罗格表现出韧性，今年迄今为止回报率达到 9%，其背后是稳健的财务状况和不断增长的股息。达维塔作为肾脏透析领域的领导者，收入和盈利能力显著增长，股票的市盈率低于其历史平均水平。这两只股票都推荐给希望在市场波动中建立多元化投资组合的投资者</p>

<p>Through a remarkable career spanning more than 70 years, Warren Buffett has demonstrated a blueprint for investing success. His disciplined approach, focusing on high-quality companies with strong fundamentals, anchored through a long-term perspective, is perhaps more important than ever amid the stock market volatility at the start of 2025.</p>
<div class="lb-trans"><p>通过超过 70 年的卓越职业生涯，沃伦·巴菲特展示了成功投资的蓝图。他的纪律性方法，专注于基本面强劲的高质量公司，并以长期视角为基础，在 2025 年初股市波动的背景下，或许比以往任何时候都更为重要。</p>
</div><p>Under Buffett's leadership, <strong>Berkshire Hathaway</strong>(NYSE: BRK.A)(NYSE: BRK.B) has crushed the returns of the <strong>S&amp;P 500</strong>(^GSPC 1.81%) over the last several decades, and is even outperforming with an impressive 9% return year to date at the time of writing. The conglomerate's stock portfolio offers retail investors a solid starting point for investment ideas.</p>
<div class="lb-trans"><p>在巴菲特的领导下，<strong>伯克希尔·哈撒韦</strong>(NYSE: BRK.A)(NYSE: BRK.B) 在过去几十年中击败了 <strong>标准普尔 500 指数</strong>(^GSPC 1.81%) 的回报，甚至在撰写时以令人印象深刻的 9% 的年初至今回报率超越了它。该集团的股票投资组合为零售投资者提供了一个坚实的投资思路起点。</p>
</div><p>Here are two Buffett stocks that I believe are strong buys right now. The best part is that you'll need less than $300 to pick up one share of each to get your portfolio started.</p>
<div class="lb-trans"><p>以下是我认为现在值得强烈购买的两只巴菲特股票。最棒的是，你只需不到 300 美元就可以购买每只股票的一股，开始你的投资组合。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MTQyMTIvZGVmZW5zaXZlLXN0b2Nrcy13YXJyZW4tYnVmZmV0dC1vd25zLmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F814212%2Fdefensive-stocks-warren-buffett-owns.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: The Motley Fool.</p>
<div class="lb-trans"><p>图片来源：The Motley Fool。</p>
</div><h2>1. Kroger</h2>
<div class="lb-trans"><h2>1. 克罗格</h2>
</div><p>Market anxiety over the strength of the U.S. economy and the looming impact of new trade tariffs introduced by the Trump administration has created a challenging investing environment this year. Yet shares of <strong>Kroger</strong>(KR 0.52%) have defied the broader stock market sell-off, delivering a 9% return year to date.</p>
<div class="lb-trans"><p>由于市场对美国经济强度的焦虑以及特朗普政府新贸易关税即将产生的影响，今年的投资环境变得具有挑战性。然而，<strong>克罗格</strong>(KR 0.52%) 的股票却逆势而上，年初至今回报率达到了 9%。</p>
</div><p>The grocery chain operates more than 2,700 stores under a variety of brands, including King Soopers, Ralphs, and Smith's. The company's profile as a leader in consumer staples, generating consistent profitability and strong underlying free cash flows, aligns with the type of investment Buffett has traditionally favored. Indeed, Berkshire Hathaway owns 7.6% of the company's outstanding shares.</p>
<div class="lb-trans"><p>这家杂货连锁店在多个品牌下运营超过 2700 家门店，包括 King Soopers、Ralphs 和 Smith's。作为消费品领域的领导者，该公司持续盈利并产生强劲的自由现金流，这与巴菲特传统上青睐的投资类型相符。实际上，伯克希尔·哈撒韦拥有该公司 7.6% 的流通股。</p>
</div><p>More importantly, Kroger's financial results and forward outlook remain solid, capturing steady demand for food that's unaffected by the trade war. For 2025, the company anticipates continued sales growth, targeting adjusted earnings per share (EPS) between $4.60 and $4.80, which represents a 5.1% increase at the midpoint compared to the previous year.</p>
<div class="lb-trans"><p>更重要的是，克罗格的财务业绩和前景依然稳健，捕捉到不受贸易战影响的食品稳定需求。对于 2025 年，该公司预计销售将持续增长，目标调整后的每股收益（EPS）在 4.60 美元至 4.80 美元之间，较去年中值增长 5.1%。</p>
</div><p>Kroger stands out as a dividend growth stock, having doubled its quarterly payment over the past five years to the current rate of $0.32 per share, yielding 1.9%.</p>
<div class="lb-trans"><p>克罗格作为一只股息增长股票脱颖而出，在过去五年中将季度支付翻倍，当前每股支付为 0.32 美元，收益率为 1.9%。</p>
</div><p>Recent comments from management express confidence in further dividend growth, alongside an ongoing share repurchase authorization. Kroger's simple yet high-quality business positions the stock for more upside, rewarding shareholders over the long term.</p>
<div class="lb-trans"><p>管理层最近的评论表达了对进一步股息增长的信心，同时还在进行股票回购授权。克罗格简单而高质量的业务为股票提供了更多上涨空间，长期回报股东。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png" alt="" original-src="https://media.ycharts.com/charts/1e964ee420c3d15214a7d1a94148298d.png"/></p>
<p>KR Dividend Yield data by YCharts</p>
<div class="lb-trans"><p>KR 股息收益率数据来源于 YCharts</p>
</div><h2>2. DaVita</h2>
<div class="lb-trans"><h2>2. 达维塔</h2>
</div><p><strong>DaVita</strong>(DVA 1.38%) is another Buffett stock that can represent a defensive investment, resilient to economic swings. This healthcare giant is one of the largest medical care providers in the United States, with an expanding presence in more than 13 other countries, specializing in kidney dialysis services.</p>
<div class="lb-trans"><p><strong>达维塔</strong>(DVA 1.38%) 是另一只可以代表防御性投资的巴菲特股票，能够抵御经济波动。这家医疗巨头是美国最大的医疗服务提供商之一，在 13 个其他国家也在不断扩展，专注于肾脏透析服务。</p>
</div><p>Serving more than 281,000 patients and performing over 29 million dialysis treatments last year, the business benefits from the recurring and life-saving nature of the treatment, covered by unique federal legislation within the End-Stage Renal Disease (ESRD) program with expanded Medicare coverage for patients in the U.S.</p>
<div class="lb-trans"><p>去年为超过 281,000 名患者提供服务，进行了超过 2900 万次透析治疗，该业务受益于治疗的重复性和救命特性，受到美国终末期肾病（ESRD）项目中独特联邦立法的覆盖，扩大了对患者的医疗保险覆盖。</p>
</div><p>It's easy to see what Buffett likes in this highly profitable industry leader. Berkshire Hathaway owns about 44% of the company's outstanding shares -- a stake it has built since its initial purchase in 2011.</p>
<div class="lb-trans"><p>很容易看出巴菲特为何喜欢这个高盈利的行业领导者。伯克希尔·哈撒韦拥有该公司约 44% 的流通股，这是自 2011 年首次购买以来逐步建立的股份。</p>
</div><p>For the full year ended Dec. 31, 2024, total revenue of $12.8 billion climbed by 5.6% year over year. Perhaps the bigger story was the jump in profitability, as adjusted EPS reached $9.68, up 26% from the year prior, driven by higher pricing and Medicare reimbursement rates. Today, DaVita stands out as a compelling investment opportunity, with a combination of sustained profitable growth and an attractive valuation.</p>
<div class="lb-trans"><p>截至 2024 年 12 月 31 日的完整年度，总收入为 128 亿美元，同比增长 5.6%。或许更大的故事是盈利能力的跃升，调整后的每股收益达到 9.68 美元，比去年增长 26%，这得益于更高的定价和医疗保险报销率。如今，达维塔作为一个引人注目的投资机会脱颖而出，结合了持续的盈利增长和吸引人的估值。</p>
</div><p>Even with the stock climbing 8% over the past year, shares are trading at just 13 times its consensus 2025 EPS as a forward price-to-earnings (P/E) ratio, well below the company's 10-year average for the earnings multiple, which is closer to 17. I believe DaVita's stock is undervalued and well-positioned to generate positive returns over the next few years -- a view Buffett might agree with.</p>
<div class="lb-trans"><p>尽管过去一年股票上涨了 8%，但其股票的交易价格仅为 2025 年每股收益的 13 倍，作为前瞻性市盈率（P/E），远低于该公司 10 年平均的收益倍数，后者接近 17。我认为达维塔的股票被低估，并且在未来几年有良好的回报潜力——这一观点巴菲特可能会赞同。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png" alt="" original-src="https://media.ycharts.com/charts/ea4cd0ca3ea0f79c9cae7172ce907e16.png"/></p>
<p>DVA PE Ratio (Forward) data by YCharts</p>
<div class="lb-trans"><p>DVA 市盈率（前瞻性）数据来源于 YCharts</p>
</div><h2>Why these stocks are winners</h2>
<div class="lb-trans"><h2>为什么这些股票是赢家</h2>
</div><p>While the stock market may be unpredictable in the short term, Buffett's steadfast patience and commitment to a long-term strategy offer a vital lesson for every investor. In my opinion, Kroger and DaVita are great stocks for a diversified portfolio to navigate any market environment.</p>
<div class="lb-trans"><p>尽管股市在短期内可能不可预测，但巴菲特坚定的耐心和对长期战略的承诺为每位投资者提供了重要的教训。在我看来，克罗格和达维塔是适合多元化投资组合的优秀股票，可以应对任何市场环境。</p>
</div>

现在用 300 美元购买的最佳沃伦·巴菲特推荐股票